Milestone Pharmaceuticals Inc.
MIST Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.69
KIRA · Stoqly’s AI analyst, in plain words
- Milestone Pharmaceuticals Inc. lost $63.1M in fiscal 2025.
- Free cash flow was −$49.3M in fiscal 2025, — of revenue.
- Milestone Pharmaceuticals Inc. has $48.8M more cash than debt.
Market cap
—
P/E
—
Revenue
—
Net income
−$63.1M
Free cash flow
−$49.3M
Operating margin
—
Milestone Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$63.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Milestone Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 20, 2026
- Legal name
- Milestone Pharmaceuticals Inc.
- CIK
- 0001408443
Milestone Pharmaceuticals Inc. · MIST
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$42.9M | −$58.4M | −$59.7M | −$41.5M | −$63.1M |
| Diluted EPS | −$1.02 | −$1.38 | −$1.39 | −$0.67 | −$0.75 |
| Cash | |||||
| Cash from operations | −$33.2M | −$52.5M | −$46.4M | −$28.8M | −$49.0M |
| Capital expenditure | — | $0.3M | $0.1M | $0.0M | $0.3M |
| Free cash flow | — | −$52.7M | −$46.5M | −$28.9M | −$49.3M |
| Debt and strength | |||||
| Cash and short-term investments | $114M | $64.6M | $66.0M | $69.7M | $106M |
| Debt incl. finance leases | — | — | $49.8M | $53.4M | $57.2M |
| Shareholders' equity | $113M | $66.3M | $16.8M | $13.1M | $41.8M |
| Current ratio | 17.6x | 11.7x | 10.1x | 9.1x | 8.0x |
| Interest coverage | — | — | −23.9x | −11.8x | −16.2x |
| Returns and quality | |||||
| Return on capital | — | — | −8,938.4% | — | — |
| Return on equity | −33.5% | −65.3% | −143.6% | −277.6% | −229.7% |
| Return on tangible equity | −38.1% | −88.0% | −355.9% | −315.8% | −151.0% |
| Altman Z'' | 14.4 | −2.7 | −13.5 | −13.7 | −9.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.2M
5 insiders
Of sales under plans
15%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Milestone Pharmaceuticals Inc. · MIST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.69 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001408443). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.